MedPath

The Benefit of Hemodialysis Plus Hemoperfusion on Mortality

Not Applicable
Completed
Conditions
End-stage Renal Disease
Interventions
Device: hemodialysis
Device: hemoperfusion combined with hemodialysis
Registration Number
NCT03227770
Lead Sponsor
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Brief Summary

This multi-center, open-label, randomized controlled trial aims to investigate the efficacy of hemoperfusion (HP) combined with hemodialysis (HD) by evaluating all-cause mortality and cardiovascular mortality in maintenance hemodialysis patients.

Detailed Description

In this HD/HPvsHD trial, we plan to enroll 1364 maintenance hemodialysis patients. Eleven medical centers in Shanghai Metropolitan area have explicitly expressed interest to participate. Participants will be randomized to receive hemodialysis plus hemoperfusion or hemodialysis alone at a 1:1 ratio after 1-month run-in period. In both arms, patients will receive lBlood purification (including low-flux hemodialysis, high-flux hemodialysis, or hemodiafiltration) treatment at least 10 hours per week. In the experiment group, in addition to the treatments in the control arm, hemoperfusion will be conducted at least once every two weeks using a HA130 resin hemoperfusion apparatus containing 130ml resin. Follow-up is scheduled at 3, 6, 12, 18, 24 and up to 48 months after randomization, and will consist the following: routine physical examinations, standard lab panels (blood routine, liver/kidney functions, tests of the coagulation system, etc.), chest X-ray, electrocardiogram, echocardiography, heart function rating (based on New York Heart Association grading). Dialysis adequacy defined by standard Kt/V will be calculated. Adverse events will be assessed according to the international conference on harmonization guidelines. The primary outcomes will include 24-month all-cause mortality. Secondary outcomes will include cardiovascular-related mortality, the occurrence of major cardiovascular events and the quality of life (Kidney Disease Quality of Life Short Form).

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
1362
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
regular hemodialysishemodialysisBlood purification (including low-flux hemodialysis, high-flux hemodialysis, or hemodiafiltration) treatment ≥10 hours per week
hemoperfusion combined with hemodialysishemoperfusion combined with hemodialysisCombination of hemodialysis and hemoperfusion treatment at least once every two week
hemoperfusion combined with hemodialysishemodialysisCombination of hemodialysis and hemoperfusion treatment at least once every two week
Primary Outcome Measures
NameTimeMethod
All-cause mortalityFrom date of enrollment until the end of study, assessed up to 24 months

Compared the difference between standardized therapy and hemoperfusion combined with hemodialysis treatment

Secondary Outcome Measures
NameTimeMethod
Cardiovascular-related mortality and major cardiovascular events (MACEs)From date of enrollment until the end of study, assessed up to 24 months

Major cardiovascular events events including angina pectoris, acute myocardial infarction, severe arrhythmia, congestive heart failure, myocarditis, pericarditis, cardiac surgery or peripheral vascular surgery, stroke and peripheral vascular disease

Evaluation of quality of lifeFrom date of enrollment until the end of study, assessed up to 24 months

Assessment of quality of life using the KDQOL-SF (Kidney Disease Quality of Life Short Form) questionnaire

Trial Locations

Locations (11)

Changhai Hospital

🇨🇳

Shanghai, Shanghai, China

Longhua Hospital Shanghai University of Traditional Chinese Medicine

🇨🇳

Shanghai, Shanghai, China

Ruijin Hospital

🇨🇳

Shanghai, Shanghai, China

Shanghai 6th People's Hospital

🇨🇳

Shanghai, Shanghai, China

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

🇨🇳

Shanghai, Shanghai, China

RenJi Hospital

🇨🇳

Shanghai, Shanghai, China

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

🇨🇳

Shanghai, Shanghai, China

Shanghai Tongji Hospital, Tongji University School of Medicine

🇨🇳

Shanghai, Shanghai, China

Shanghai Zhongshan Hospital

🇨🇳

Shanghai, Shanghai, China

Yangpu District Central Hospital Affiliated to Tongji University

🇨🇳

Shanghai, Shanghai, China

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

🇨🇳

Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath